果酱视频

The global pharmaceutical-grade melatonin market opened on a softer note in May of 2025 with notable price corrections was seen across key markets. The market has displayed a subdued tone as prices were in a downward trend. This was followed by shifts in demand from downstream pharmaceutical, nutraceutical and food & beverage sectors. The 2^nd week of May reflected this market softness with melatonin quotations softening in the US, China and Indian market. The overall environment was characterized by uninterrupted production cycles and steady supply which provided sufficient availability to meet market requirements without inciting upward pricing pressure.

果酱视频 looked deeper into the melatonin market fundamentals and observed that the current situation stemmed from a combination of strategic inventory management by buyers and cautious procurement behaviour within downstream industries. There was a substantial stock levels that had been carried into May after the conclusion of previous production cycles which reduced the immediate replenishment requirements. Simultaneously, the new production cycles commenced without disruptions and ensured consistent output volumes from major manufacturing hubs. This uninterrupted supply availability of melatonin with soft demand from pharmaceutical companies, nutraceutical producers and functional food manufacturers resulted in the softening of prices. The end-user demand was restrained as market participants adjusted their purchasing schedules in anticipation of future seasonal consumption cycles typically seen during mid-year pharmaceutical production.

The market of Melatonin in China, FOB Shanghai recorded a 0.95% price dip during the 2^nd week of May. This adjustment was attributed to strategic pricing measures adopted by suppliers who tried to maintain competitiveness amid balanced domestic and export demand. The suppliers opted for marginal downward revisions to secure transactional volumes and mitigate inventory buildup as the production continued smoothly and downstream pharmaceutical and nutraceutical formulation demand remained moderate. The India鈥檚 Ex-Mumbai market experienced a sharper decline of 1.25% in the prices of Melatonin. The domestic pharmaceutical segment displayed a conservative buying pattern. The import volumes remained modest and contributed limited pressure on local availability. The absence of aggressive demand from nutraceutical manufacturers further eased the pricing momentum.

The USA market of Melatonin saw the most pronounced correction with a decline of 2.13% at FOB New York. The buyers maintained a cautious stance and managed inventory levels judiciously amid sufficient stocks carried over from earlier months. The pharmaceutical sector鈥檚 moderate consumption rates and strategic purchasing delays by nutraceutical product formulators softened the immediate market demand. There was uninterrupted domestic production which created a surplus availability and compelled sellers to offer competitive price concessions to sustain order volumes.

果酱视频 anticipates that the melatonin prices will likely stabilize through late May and early June. The recent price fluctuations听 for melatonin can be logically linked to transitional market behaviour where downstream buyers deliberately reduced procurement volumes to balance inventories before the upcoming mid-year demand cycle. The demand is expected to normalize as the existing melatonin stocks will get absorbed and fresh production cycles align with the forecasted pharmaceutical and nutraceutical product launches for summer and early autumn.